Welcome to the Wet AMD & DME Drug Development Summit
Running virtually for 2021, the inaugural Wet AMD & DME Drug Development Summit comes at a critical juncture, as the research community progresses novel drug candidates targeting angiogenesis-driven disease and a pandemic further exposes the current treatment limitations for a global aging population.
Join this dedicated industry forum, to network online and learn from senior leaders of discovery, translational sciences, and clinical development from the likes of Boehringer Ingelheim, Doheny Eye Institute, Aerpion Therapeutics, Genentech, Ocugen and more to address the specific challenges for the biopharmaceutical and biotechnology in its efforts to bring long-lasting treatments which reduce clinical burden and can be commercialized to become the new standard-of-care in this vast ophthalmology indication.
Navigate across 3 jam-packed days including interactive workshops exploring clinical biomarkers for testing drugs in patients and developing preclinical models to predict human disease and efficacy of a drug.
Companies Registered to Attend Include:
Expert Speakers Include:
Feedback from the Dry AMD Therapeutic Development Summit:
“Thorough update on the scientific, regulatory and commercial status of dry AMD”
CEO, Drusolv Therapeutics
“Informative and enlightening”
Chief Medical Officer, Eyevensys